{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:20:49Z","timestamp":1773796849540,"version":"3.50.1"},"reference-count":76,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS)","doi-asserted-by":"publisher","award":["JP17K15511"],"award-info":[{"award-number":["JP17K15511"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS)","doi-asserted-by":"publisher","award":["JP18H02604"],"award-info":[{"award-number":["JP18H02604"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Although a lot of effort has been put into creating drugs and combination therapies against chronic hepatitis, no effective treatment has been established. Type-I interferon is a promising therapeutic for chronic hepatitis due to its excellent anti-inflammatory effects through interferon receptors on hepatic macrophages. To develop a type-I IFN equipped with the ability to target hepatic macrophages through the macrophage mannose receptor, the present study designed a mouse type-I interferon-mannosylated albumin fusion protein using site-specific mutagenesis and albumin fusion technology. This fusion protein exhibited the induction of anti-inflammatory molecules, such as IL-10, IL-1Ra, and PD-1, in RAW264.7 cells, or hepatoprotective effects on carbon tetrachloride-induced chronic hepatitis mice. As expected, such biological and hepatoprotective actions were significantly superior to those of human fusion proteins. Furthermore, the repeated administration of mouse fusion protein to carbon tetrachloride-induced chronic hepatitis mice clearly suppressed the area of liver fibrosis and hepatic hydroxyproline contents, not only with a reduction in the levels of inflammatory cytokine (TNF-\u03b1) and fibrosis-related genes (TGF-\u03b2, Fibronectin, Snail, and Collagen 1\u03b12), but also with a shift in the hepatic macrophage phenotype from inflammatory to anti-inflammatory. Therefore, type-I interferon-mannosylated albumin fusion protein has the potential as a new therapeutic agent for chronic hepatitis.<\/jats:p>","DOI":"10.3390\/ph17020260","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T10:40:15Z","timestamp":1708339215000},"page":"260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis"],"prefix":"10.3390","volume":"17","author":[{"given":"Yuki","family":"Minayoshi","sequence":"first","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Hamasaki","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisei","family":"Nagasaki","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Mizuta","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan"},{"name":"Public Health and Welfare Bureau, 5-1-1 Oe, Chuo-ku, Kumamoto 862-0971, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan"},{"name":"Osaka Central Hospital, 3-3-30 Umeda, Kita-ku, Osaka 530-0001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan"},{"name":"DDS Research Institute, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-4144","authenticated-orcid":false,"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto 862-0973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/1440-1681.12976","article-title":"Chronic moderate alcohol consumption relieves high-fat high-cholesterol diet-induced liver fibrosis in a rat model","volume":"45","author":"Sun","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jhep.2004.12.008","article-title":"Fibrosis in chronic liver diseases: Diagnosis and management","volume":"42","author":"Pinzani","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Science in medicine Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_9","first-page":"1700","article-title":"Immunizing property of vaccinia virus inactivated by ultraviolets rays","volume":"148","author":"Nagano","year":"1954","journal-title":"Comptes Rendus Seances Soc. Biol. Ses Fil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108211","DOI":"10.1016\/j.celrep.2020.108211","article-title":"Interferon-\u03bb Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway","volume":"33","author":"Syedbasha","year":"2020","journal-title":"Cell Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.24059","article-title":"Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells","volume":"53","author":"Petrasek","year":"2011","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.26981","article-title":"Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis","volume":"60","author":"Roh","year":"2014","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4049\/jimmunol.1800129","article-title":"IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells","volume":"201","author":"Xiao","year":"2018","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3389\/fimmu.2018.02129","article-title":"Interferon-\u03b1 Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling","volume":"9","author":"Bazhin","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20180325","article-title":"Type I interferons in tuberculosis: Foe and occasionally friend","volume":"215","author":"Sher","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: Friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.dld.2011.02.014","article-title":"Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity","volume":"43","author":"Yasui","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1015396825274","article-title":"Pharmaceutical strategies utilizing recombinant human serum albumin","volume":"19","author":"Chuang","year":"2002","journal-title":"Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","article-title":"Albumin nanostructures as advanced drug delivery systems","volume":"13","author":"Karimi","year":"2016","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_23","unstructured":"Kragh-Hansen, U. (2016). Albumin Medicine: Pathological and Clinical Applications, Springer."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2174\/1381612822666160125114900","article-title":"Albumin-Based Nanodevices as Drug Carriers","volume":"22","author":"Loureiro","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jconrel.2011.11.028","article-title":"Clinical impact of serum proteins on drug delivery","volume":"161","author":"Kratz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2010.03.010","article-title":"Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics","volume":"145","author":"Hirata","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.114.219493","article-title":"Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+\/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models","volume":"352","author":"Maeda","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1248\/bpb.b19-00599","article-title":"Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model","volume":"43","author":"Maeda","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jconrel.2021.11.039","article-title":"Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH","volume":"341","author":"Maeda","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/10717544.2018.1464083","article-title":"Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions","volume":"25","author":"Minayoshi","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0023677215571192","article-title":"The carbon tetrachloride model in mice","volume":"49","author":"Scholten","year":"2015","journal-title":"Lab. Anim."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1248\/bpb.b23-00254","article-title":"Therapeutic Effects of Albumin-Fused BMP7 on 2 Experimental Models of Liver Fibrosis","volume":"46","author":"Takano","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"ref_34","unstructured":"Recknagel, R.O., Glende, E.A., and Britton, R.S. (2020). Hepatotoxicology, CRC Press."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/taap.2001.9304","article-title":"The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride","volume":"177","author":"Simeonova","year":"2001","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3523642","DOI":"10.1155\/2018\/3523642","article-title":"Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation","volume":"2018","author":"Lu","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients with Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_38","first-page":"303","article-title":"Hepatoprotective and Anti-fibrotic Agents: It\u2019s Time to Take the Next Step","volume":"6","author":"Weiskirchen","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/17512433.2015.1090872","article-title":"Treatment discontinuation with peg-interferon: What to consider","volume":"8","author":"Boccaccio","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","article-title":"Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B","volume":"14","author":"Huang","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Qin, A., Wu, C.R., Ho, M.C., Tsai, C.Y., and Chen, P.J. (2023). Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202312.0417.v3"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10147-009-0003-7","article-title":"Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes","volume":"15","author":"Miwa","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.yexcr.2011.03.002","article-title":"Beta-interferon for multiple sclerosis","volume":"317","author":"Rudick","year":"2011","journal-title":"Exp. Cell Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2017.00410","article-title":"The Protective Role of Type I Interferons in the Gastrointestinal Tract","volume":"8","author":"Kotredes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3748\/wjg.v11.i17.2634","article-title":"Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis","volume":"11","author":"Chang","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(98)80012-3","article-title":"Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats","volume":"29","author":"Fort","year":"1998","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep.1840380415","article-title":"Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice","volume":"38","author":"Inagaki","year":"2003","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/hep.1840210418","article-title":"Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture","volume":"21","author":"Mallat","year":"1995","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12072-009-9129-y","article-title":"Effect of natural interferon \u03b1 on proliferation and apoptosis of hepatic stellate cells","volume":"3","author":"Ogawa","year":"2009","journal-title":"Hepatol. Int."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Shen, H., Zhang, M., Minuk, G.Y., and Gong, Y. (2002). Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol., 3.","DOI":"10.1186\/1471-2121-3-9"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2567.2007.02672.x","article-title":"Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects","volume":"122","author":"Tanabe","year":"2007","journal-title":"Immunology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1073\/pnas.89.17.8225","article-title":"Alloalbuminemia in Sweden: Structural study and phenotypic distribution of nine albumin variants","volume":"89","author":"Carlson","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cca.2014.11.003","article-title":"Novel silent albumin variant (191Ala \u27f6 Thr) detected by TOF MS of whole plasma","volume":"440","author":"Brennan","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0925-4439(91)90023-3","article-title":"Structural characterization of a glycoprotein variant of human serum albumin: Albumin Casebrook (494 Asp \u27f6 Asn)","volume":"1097","author":"Peach","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1073\/pnas.87.1.26","article-title":"Albumin Redhill (-1 Arg, 320 Ala \u27f6 Thr): A glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site","volume":"87","author":"Brennan","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12328-018-0915-8","article-title":"Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: A case report","volume":"12","author":"Yoshida","year":"2019","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2010.11.011","article-title":"The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity","volume":"12","author":"Stienstra","year":"2010","journal-title":"Cell Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JAD-180814","article-title":"Thioredoxin-Interacting Protein (TXNIP) Associated NLRP3 Inflammasome Activation in Human Alzheimer\u2019s Disease Brain","volume":"68","author":"Li","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/ene.14338","article-title":"Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis","volume":"27","author":"Yuan","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_62","first-page":"41","article-title":"[IL-1Ra: Its role in rheumatoid arthritis]","volume":"56","author":"Cutolo","year":"2004","journal-title":"Reumatismo"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: Results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13318-018-0523-5","article-title":"Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects","volume":"44","author":"Xie","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcp.2018.05.007","article-title":"Quercetin ameliorates kidney injury and fibrosis by modulating M1\/M2 macrophage polarization","volume":"154","author":"Lu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhang, M., Nakamura, K., Kageyama, S., Lawal, A.O., Gong, K.W., Bhetraratana, M., Fujii, T., Sulaiman, D., Hirao, H., and Bolisetty, S. (2018). Myeloid HO-1 modulates macrophage polarization and protects against ischemia-reperfusion injury. JCI Insight, 3.","DOI":"10.1172\/jci.insight.120596"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2957\/kanzo.60.459","article-title":"Acutely exacerbated chronic hepatitis C after administration of nivolumab: A case report","volume":"60","author":"Takahashi","year":"2019","journal-title":"Kanzo"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"30269","DOI":"10.3390\/ijms161226225","article-title":"Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine","volume":"16","author":"Moura","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cvsm.2003.09.015","article-title":"Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders","volume":"34","author":"Center","year":"2004","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis","volume":"20","author":"Zhou","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fimmu.2014.00221","article-title":"Role of toll-like receptors in immune activation and tolerance in the liver","volume":"5","author":"Nakamoto","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_73","first-page":"1","article-title":"Emerging roles for lipids in the hepatic innate immune response","volume":"1","author":"Moore","year":"2013","journal-title":"Hum. Nutr. Food. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.171.1.285","article-title":"IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3","volume":"171","author":"Schaefer","year":"2003","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/2\/260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:01:53Z","timestamp":1760104913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/2\/260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":76,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ph17020260"],"URL":"https:\/\/doi.org\/10.3390\/ph17020260","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}